Literature DB >> 22041644

Femoral neck fractures in patients on Clopidogrel. The effect of delaying surgery and the introduction of the new SIGN guidelines.

Andreas Leonidou1, Nicholas Boyce Cam, Iain Robert Chambers.   

Abstract

INTRODUCTION: Femoral neck fractures are an increasingly common injury in the elderly. Frequently these patients present taking Clopidogrel, an irreversible inhibitor of platelet aggregation. Although this is associated with an increased risk of intra-operative bleeding and also an increased risk of spinal haematoma where regional anaesthesia is employed, the recent SIGN (Scottish Intercollegiate Guidance Network) guidelines recommend that surgery should not be delayed.
METHODS: We conducted a retrospective review of consecutive patients admitted with femoral neck fractures between April 2008 and October 2009. Patients on Clopidogrel were identified and data including ASA grade, time to operation, medical co-morbidities, and post-admission complications were recorded. Comparative information from the National Hip Fracture Database was used.
RESULTS: 405 patients were included. 27 patients were taking Clopidogrel on admission and they were all ASA 3 or 4. Mean time to theatre was 8 days. Post-admission medical complications occurred in 7 patients (25.9%). A further 4 patients (14.8%) died, 3 of them post-operatively. From the study population a control group of 72 ASA 3 and 4 patients was further studied. The mean time to operation was 2.3 days. Post-admission medical complications occurred in 13 patients (18%) and 8 patients (11%) died post-operatively. The difference in the mortality and morbidity of these two groups was found to be statistically not significant. In 2009 the national mean time to operation was 2.19 days with an associated mortality rate of 8.67%. DISCUSSION AND
CONCLUSION: Patients receiving Clopidogrel have complex medical co-morbidities and a higher anaesthetic risk. Delaying operative management might be contributing to the increased rate of mortality and morbidity. In accordance with the SIGN guidelines we recommend early operative intervention in these high risk patients. Copyright Â
© 2010 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22041644     DOI: 10.1016/j.surge.2010.11.030

Source DB:  PubMed          Journal:  Surgeon        ISSN: 1479-666X            Impact factor:   2.392


  6 in total

1.  Effect of early surgery in high surgical risk geriatric patients with femoral neck fracture and taking antiplatelet agents.

Authors:  Paphon Sa-Ngasoongsong; Noratep Kulachote; Norachart Sirisreetreerux; Pongsthorn Chanplakorn; Sukij Laohajaroensombat; Nithiwut Pinsiranon; Patarawan Woratanarat; Viroj Kawinwonggowit; Chanyut Suphachatwong; Wiwat Wajanavisit
Journal:  World J Orthop       Date:  2015-12-18

Review 2.  The Perioperative Management of Antiplatelet and Anticoagulant Drugs in Hip Fractures: Do the Surgery as Early as Possible.

Authors:  Mohammad Ali Ghasemi; Ehsan Ghadimi; Ahmad Shamabadi; Sm Javad Mortazavi
Journal:  Arch Bone Jt Surg       Date:  2022-06

3.  Safety of clopidogrel in hip fracture surgery.

Authors:  Molly A Feely; Tad M Mabry; Christine M Lohse; Stephen A Sems; Karen F Mauck
Journal:  Mayo Clin Proc       Date:  2013-02       Impact factor: 7.616

4.  Decision making on timing of surgery for hip fracture patients on clopidogrel.

Authors:  B Purushothaman; M Webb; A Weusten; S Bonczek; J Ramaskandhan; A Nanu
Journal:  Ann R Coll Surg Engl       Date:  2016-02       Impact factor: 1.891

5.  Is hip fracture surgery safe for patients on antiplatelet drugs and is it necessary to delay surgery? A systematic review and meta-analysis.

Authors:  Zhanyu Yang; Jiangdong Ni; Ze Long; Letian Kuang; Yongquan Gao; Shibin Tao
Journal:  J Orthop Surg Res       Date:  2020-03-12       Impact factor: 2.359

Review 6.  Clopidogrel and hip fractures, is it safe? A systematic review and meta-analysis.

Authors:  Christopher G K M Soo; Paul K Della Torre; Tristan J Yolland; Michael A Shatwell
Journal:  BMC Musculoskelet Disord       Date:  2016-03-22       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.